165 related articles for article (PubMed ID: 16815703)
1. State of the art therapy in multiple myeloma and future perspectives.
Denz U; Haas PS; Wäsch R; Einsele H; Engelhardt M
Eur J Cancer; 2006 Jul; 42(11):1591-600. PubMed ID: 16815703
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
Engelhardt M; Kleber M; Udi J; Wäsch R; Spencer A; Patriarca F; Knop S; Bruno B; Gramatzki M; Morabito F; Kropff M; Neri A; Sezer O; Hajek R; Bunjes D; Boccadoro M; Straka C; Cavo M; Polliack A; Einsele H; Palumbo A
Leuk Lymphoma; 2010 Aug; 51(8):1424-43. PubMed ID: 20509769
[TBL] [Abstract][Full Text] [Related]
3. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
4. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
Bensinger W
J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
[TBL] [Abstract][Full Text] [Related]
5. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
6. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
7. Targeted treatments to improve stem cell outcome: old and new drugs.
Raab MS; Breitkreutz I; Anderson KC
Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
[TBL] [Abstract][Full Text] [Related]
8. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Lonial S; Cavenagh J
Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
[TBL] [Abstract][Full Text] [Related]
9. The evolution and impact of therapy in multiple myeloma.
Laubach JP; Richardson PG; Anderson KC
Med Oncol; 2010 Jun; 27 Suppl 1():S1-6. PubMed ID: 20169425
[TBL] [Abstract][Full Text] [Related]
10. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
12. Future challenges.
Sirohi B; Powles R
Bone Marrow Transplant; 2007 Dec; 40(12):1157-64. PubMed ID: 17906703
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
14. An update: health economics of managing multiple myeloma.
Moeremans K; Annemans L
Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
[TBL] [Abstract][Full Text] [Related]
15. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
16. Role of autologous stem-cell transplantation in multiple myeloma.
Attal M; Harousseau JL
Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
Mehta J; Singhal S
Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N; Badbaran A; Lioznov M; Schwarz S; Zeschke S; Hildebrand Y; Ayuk F; Atanackovic D; Schilling G; Zabelina T; Bacher U; Klyuchnikov E; Shimoni A; Nagler A; Corradini P; Fehse B; Zander A
Exp Hematol; 2009 Jul; 37(7):791-8. PubMed ID: 19487069
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
Kumar L; Ghosh J; Ganessan P; Gupta A; Hariprasad R; Kochupillai V
Bone Marrow Transplant; 2009 Mar; 43(6):481-9. PubMed ID: 18978818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
